Histone deacetylase inhibitors (HDACIs) are a promising new class of anticancer drugs.
Histone deacetylase inhibitors and genomic instability.

Introduction:
Although the presence of acetyl groups on histones and their role in transcription was first reported more than forty years ago [1; 2] , the function of protein acetylation/deacetylation remained a relatively neglected field over the following thirty years. Since the identification of the first histone acetyltransferases (HATs) and histone deacetylases (HDACs) and their respective functions in regulation of transcription in the mid-90s [3] [4] [5] [6] [7] [8] [9] , interest in previously overlooked protein post-translational modifications has been renewed [10] [11] [12] [13] . There is now a growing body of evidence that protein acetylation is involved in a large number of cell signaling pathways, reminiscent of protein phosphorylation [14] . Protein acetylation is catalyzed by HATs, which transfer an acetyl group from acetyl-CoA to the ε-amino group of a lysine; the reverse reaction, involving the deacetylation of acetylated lysines, is mediated by
HDACs. Acetylation and deacetylation by HATs and HDACs were first described for histones. However, these processes occur in bacteria [15; 16] , which do not have histones.
Indeed, a rapidly growing number of non-histone proteins have been found to be regulated by acetylation/deacetylation [17; 18] .
There are four classes of HDAC in humans: class I HDACs (HDAC1, 2, 3 and 8) share sequence similarity with the yeast RPD3 deacetylase, are ubiquitously expressed and localized in the nucleus. Class II HDACs (HDAC4, 5, 6, 7, 9 and 10) are homologous to the yeast Hda1 deacetylase, are mainly cytoplasmic (or both nuclear and cytoplasmic) and
restricted to certain tissues [19] . Class II HDACs are subdivided into two subclasses, class IIa (HDAC4, 5, 7 and 9) and class IIb (HDAC6 and 10). Class III HDACs are represented by sirtuins (SIRT1 to SIRT7), a family of seven HDACs sharing homology with yeast silent information regulator 2 (Sir2) [20] . In addition to their deacetylase activity, some sirtuins are able to transfer ADP-ribose from NAD+ to an acetylated protein target. Class IV has only one member, HDAC11, which shares conserved residues with both class I and II HDACs [21] .
Class I, II and IV HDACs activity requires Zn 2+ and can be inhibited by a variety of different pharmacological HDAC inhibitors (HDACIs) [22] , whereas class III enzymes are NAD+dependent deacetylases with only a limited number of inhibitors described [20; 23] . Class I, II
and IV HDAC-specific inhibitors have antiproliferative activity and several are currently being tested in clinical trials, alone or in combination with other therapies, for their antitumor properties [24; 25] . There is now accumulating evidence of anticancer activity in myeloid malignancies and solid tumors for several HDACIs (reviewed in [26; 27] ) and the first HDACI to obtain FDA approval for cancer therapy was suberoylanilide hydroxamic acid (SAHA, vorinostat), which was effective for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma in clinical trials [28] . Although HDACIs represent a new class of very promising anticancer drugs, their pleiotropic effects on a variety of cell functions make it difficult to identify the precise mechanism(s) underlying their antiproliferative properties. The most obvious target for HDACIs is gene expression; indeed, previous studies suggest that HDACI treatment (valproic acid, trybutirine, sodium butyrate [29] and SAHA [30] ) leads to the reexpression of silenced tumor-suppressor genes, such as the p21(WAF1/CIP1)-encoding gene, in cancer cells. Some other specific targets for particular HDACIs have also been described. For example, treatment with valproic acid, but not trichostatin A (TSA), selectively induce proteasome dependent HDAC2 degradation [31] . However, potential downstream targets of HDACIs include various aspects of the cell cycle, DNA recombination and repair, extrinsic and intrinsic apoptosis pathways, angiogenesis, autophagy and senescence, among others; and it is not clear whether transcription mediates HDACI action in these processes [32] . Only a relatively small proportion of genes are up-or down-regulated following treatment with the HDACIs TSA [33] [34] [35] , SAHA and MS-275 [34] and non-transcriptional targets have been proposed [36; 37] .
A substantial number of studies have demonstrated a synergistic effect of conventional and HDACI-based therapies. In particular, HDACI treatments sensitize cycling cells to irradiation and DNA-targeting drugs, possibly resulting from HDACI-induced chromatin remodeling.
Additionally, HDACIs seem to impair a variety of cellular processes that ensure genome stability, such as the control of DNA damage and repair, the regulation of reactive oxygen species (ROS) concentration and the progression into mitosis (relevant HDACIs and their known effects on genomic instability are listed on Table 1 ). Targeting genome integrity in rapidly cycling cells has always been a preferred strategy in cancer therapy; thus, in this review, we will focus on the different aspects of genome instability induced by pharmacological inhibition of Zn 2+ -dependent HDACs.
HDACIs and DNA damage and repair.
There is no evidence suggesting that HDACIs have direct mutagenic or clastogenic properties.
However, histone hyperacetylation induced by HDAC inhibition causes profound changes in chromatin structure. These changes may expose sections of DNA that are normally protected from damage in tightly packed chromatin. HDAC inhibition may also affect the expression of DNA repair genes and disrupt their finely-tuned expression timing, leading to improper cellular responses to DNA damage and accumulation of strand breaks and modified bases.
Moreover, the activity of certain DNA repair proteins may be directly regulated by acetylation, resulting in a shift of the cellular acetylation/deacetylation balance towards hyperacetylation, and impaired DNA repair function. Thus, HDAC inhibition may indirectly exert clastogenic and mutagenic effects through DNA exposure and abnormal regulation of the DNA repair machinery.
Sensitization to exogenous DNA damage by HDACI.
Early observations indicated that the HDACI sodium butyrate enhances cell radiosensitivity in vitro [38] [39] [40] . Since these findings and the development of HDACIs as anticancer drugs, the number of studies reporting synergistic action between ionizing irradiation (IR) and HDACIs in cancer cell lines or animal pre-clinical models has grown exponentially. Various HDACIs, belonging to different chemical classes, appear to sensitize cultured cancer cells to IR (reviewed in [41] ). In mouse xenograft models, the combination of HDACI treatment (MS-275 [42] , valproic acid [43] , LBH589 [44] , LAQ824 [45] and AN-9 [46] ) with radiation therapy, results in a greater delay in tumor growth than that accounted for by a simple additive effect of the corresponding individual treatments. HDAC inhibition by LBH589 [44] , TSA [47] , depsipeptide [48] and SAHA [49] stabilizes and enhances IR-induced phosphorylated histone H2AX nuclear foci, classical markers of DSBs, suggesting that HDACIs inhibit DSB repair and/or render DNA more susceptible to IR-induced damage. HDACIs facilitate radiation-induced killing in tumor cells and at the same time appear to protect healthy tissues from cutaneous radiation syndrome. Although this hinders our understanding of the mechanisms involved, it will be a significant benefit for future therapies [50] .
HDACIs such as HC-toxin, MS-275, SAHA and TSA also promote the induction of cell death by a variety of DNA-targeting drugs such as mitomycin C, cisplatin, bleomycin, topotecan, doxorubicin, etoposide, 5-fluorouracil and Ara-C [51; 52] . An HC-toxin induced increase in phosphorylated H2AX foci was observed for all drugs that directly, or indirectly, cause DSBs (mitomycin C, cisplatin, bleomycin, topotecan, doxorubicin and etoposide) [52] . This further supports the notion that HDAC inhibition stabilizes DSBs and/or increases DNA sensitivity to DSBs. In fission yeast, strains mutated for components of HDAC complexes are highly sensitive to genotoxic agents, with a massive accumulation of DSBs [53] . The same study also demonstrated that these strains increase antisense transcripts, suggesting that DSBs could be triggered by the presence of RNA-DNA hybrids, structures known to induce genomic instability [54] .
HDACI and double strand break repair machinery.
Spontaneous endogenous DNA double-strand breaks occur at the surprisingly high rate of 50
DSBs per cell and per generation in normal cells [55] . [66] . In this study, TSA did not sensitize BRCA1null cells to irradiation, whereas a cell line complemented with a BRCA1 wild-type allele showed a TSA-dependent enhanced susceptibility to IR, suggesting that down-regulation of BRCA1 is a key event in HDACI-induced radiosensitization [66] . However, the picture is likely to be much more complex since this study did not detect a change in gene expression for the key strand transfer protein RAD51, whereas another group found that it was downregulated to one third of its normal levels following treatment with PCI-24781, another broadspectrum HDACI [67] . Consistent with HDACI-induced RAD51 depletion, treated cells exhibited HR repair defects and NHEJ mutant cells were hypersensitive to PCI-24781 [67] .
As recentely reported, deletion of a particular HDAC, HDAC3, in mouse embryonic fibroblasts affects S phase progression and causes DNA breaks, perhaps by disrupting DNA repair [68] . Consequentely, HDAC3 may represent an important target for HDACIs in terms of genomic instability.
Thus, HDAC inhibition seems to promote the generation and stabilization of DNA DSBs by a pleiotropic mechanism. It sensitizes DNA to exogenous genotoxic damage, impairs the "DNA-damage histone code" function and down-regulates the activity of DNA repair machinery, either by acting on the expression of the corresponding genes or by directly inactivating the components by acetylation.
HDACI-induced oxidative stress.
Reactive oxygen species (ROS), such as superoxide anion, hydrogene peroxide or hydroxyl radicals, represent a major source of endogenous DNA damage. Normal cells control ROS concentrations through the actions of enzymatic and non-enzymatic ROS scavengers.
However, cells with particularly high ROS concentrations, or with defective ROS scavengers, enter a state of genotoxic oxidative stress which often leads to apoptosis. The most widely studied mechanism of ROS-induced mutagenesis is base oxidation. Oxidized bases are normally removed by glycosylases. The resulting abasic site is then recognized by an APendonuclease, which makes an incision on the DNA strand, generating a single-strand break (SSB) (reviewed in [69] ). SSBs, which can also result from the direct oxidative damage of the nucleotide's sugar component [70] , are normally efficiently repaired to prevent their conversion into potentially lethal DSBs during DNA replication or transcription [71] .
A number of studies have reported that HDAC inhibition by several HDACIs such as SAHA, 
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HDACIs and control of chromosome segregation.
Mitosis is a common target in anticancer therapy, as illustrated by the success of microtubule targeting drugs such as vinca alkaloids or taxanes. Inhibition of the main mitotic segregation control mechanism, the spindle assembly checkpoint (SAC), using RNA interference, leads to cell death in a few generations [79] . Thus, forcing rapidly cycling cells towards aneuploidy by damaging chromosome segregation control mechanisms may represent a novel therapeutic strategy. It now clear that HDAC inhibition also impairs the control of mitotic progression, supporting the potential development of novel HDACI-based anticancer therapy targeting mitosis.
HDACI effects on mitosis.
Cells treated in culture with HDACI often display mitotic defects. One of the most striking effects of HDACI treatment is the disruption of pericentric heterochromatin associated with chromosomal segregation defects. Long-term incubation in TSA leads to loss of the heterochromatin-specific factor HP1 and to the appearance of lagging chromosomes [80] .
HP1 proteins normally bind to a site encompassing histone H3 tri-methylated at lysine 9 by the histone methyl-transferase Suv39h [81; 82] . In fission yeast, HP1 and Suv39h orthologs are required for centromeric chromatid cohesion [83; 84] . It is thus possible that TSA-induced segregation defects result from abnormal acetylation of histone H3 on lysine 9, which would prevent Suv39h tri-methylation and inhibit HP1binding. Failure to bind HP1 proteins would in turn hamper heterochromatin formation and sister chromatid cohesion. However, a recent study demonstrated that, in contrast with fission yeast, the Suv39h-HP1 pathway is not required for chromatid cohesion in mammalian cells [85] , suggesting that TSA-induced heterochromatin disruption and segregation defects may be unrelated.
TSA-treated cells also exhibit chromosome condensation defects. Short-term treatment with high doses of TSA induces heterogeneity in chromosome condensation in all mitotic stages, associated with a delay in prophase progression and the occurrence of lagging chromosomes and chromatid bridges in anaphase [86] . In a Xenopus oocyte maturation system commonly used to mimic mitosis, TSA treatment impedes chromosome condensation without preventing meiosis progression [87] . Chromosome condensation is an essential step to eliminate DNA catenation at prophase and prevent chromosome missegregation at anaphase. The condensation defects observed following HDAC inhibition may thus contribute to the segregation defects reported.
HDAC inhibition may also disrupt mitosis by acting on mitotic kinases or their substrates.
The class I histone deacetylase, HDAC3, targets chromosomes and associates with the mitotic kinase, Aurora B, during mitosis. Selective down-regulation of HDAC3 leads to a decrease of Aurora B-dependent phosphorylation of histone H3 on serine 10, and causes G2/M delay and segregation defects. The involvement of HDAC3 in providing a hypoacetylated histone H3 Nterminal tail, the preferred substrate for Aurora B, has been suggested [88] . HDAC3 also seems to be involved in microtubule-kinetochore attachment and, may therefore have critical functions in different functional subcompartments during mitosis [89] . However the picture may be more complex since a recent study reported that, although HDAC3 knockout leads to embryonic lethality, no mitosis defects were observed in HDAC3 -/embryonic fibroblasts while these cells appear to be defective in DSB repair. [68] . Another mitotic kinase often overexpressed in cancer cells, Aurora A, may also represent a target for HDACIs. A recent study showed that the HDACIs LAQ824 and SK-7068 induced tumor-selective mitotic toxicity by depleting Aurora A. Treated cells had spindle defects and the mechanism by which Aurora A was down-regulated following treatment may involve stimulation of proteasomedependent degradation of Aurora A [90] . Mitotic spindle defects have also been reported using other HDACIs such as SBHA, SAHA, sodium butyrate and TSA [91] .
The spindle assembly checkpoint.
Among their many effects, HDACIs appear to be potent pharmacological inhibitors of an essential segregation control mechanism: the mitotic spindle assembly checkpoint (SAC). The SAC maintains cells in mitosis with attached sister chromatids by preventing cyclin B and securin proteasome-dependent degradation until all kinetochores have been captured by spindle microtubules and tension is established between sister kinetochores (reviewed in [92] [95] [96] [97] . In line with these findings, HDACIs (TSA, apicidin and sodium butyrate) induce premature sister chromatid separation [95] , a phenotype consistently observed when the SAC is inhibited by RNA interference or genetic means [98] [99] [100] . Securin proteasome-dependent degradation is also observed in TSA treated mitotic cells and most likely accounts for premature sister chromatid separation [95] . A recent study reported that SBHA treatment results in failure to properly recruit the chromosomal passenger complex (CPC) at centromeres. Given that survivin and Aurora B, two essential CPC componants, control SAC protein localization [101] [102] [103] , it was proposed that the HDACI-induced overriding of SAC results from CPC mistargeting [91] . Consistent with a role for HDACI in inhibiting the SAC, a synergistic effect of a combination of microtubule-targeting drugs with TSA has been reported [96] . Together, these findings demonstrate that HDAC inhibition leads to SAC dysfunction, providing a possible explanation for the previous observations that HDACIs treatments induce segregation defects and polyploidy [80; 86; 97; 104].
Conclusions and future directions.
HDACIs appear to affect genome stability by targeting various cellular mechanisms of genome surveillance (outlined on Figure 1 ). Targeting chromosome segregation to fight cancer may seem an attractive strategy but it must be remembered that forcing cells to chromosome missegregation is a double-edged sword since it appears to be both oncogenic and anti-oncogenic. As a matter of fact, mice heterozygous for the SAC components MAD1 and MAD2 are more susceptible to spontaneous tumors [99; 107] , while down regulation of SAC component leads to proliferative cell death in an in vitro assay [79] . It was proposed that moderate chromosome missegregation could be tumorigenic while massive missegregation would lead to tumor suppression [108] . A recent and elegant study reports that mice heterozygous for the SAC component CENP-E had an increase incidence of spleen lymphomas and lung adenomas.
However, the same animals had a decreased incidence of spontaneous liver cancers and of cancers chemically or genetically induced [109] . Thus, within the same organism, chromosome missegregation can act both as a tumor promoter and a tumor suppressor, depending on the cell type and the genetic and environmental contexts. This dual potential should be kept in mind when optimizing therapeutic protocols intended to target chromosome segregation for cancer therapy.
Thus, the pleiotropic effect of nonspecific HDAC inhibition may hamper treatment targeting a given cellular function such as transcription, DNA repair or mitosis. As a consequence, the identification of the individual HDACs involved in these functions and the design of specific
HDACIs that target single, or a small subset of, HDAC(s) remains a priority. Potential functional HDACI targets are boxed. See text for details on each mechanism. NHEJ, Non-Homologous-End-Joining; HR, Homologous Recombination. 
